Market Dynamics:

Driver: Rising incidence and prevalence of cancer

Globally, there has been a significant increase in diagnosis of people suffering from cancer. The rising prevalence of cancer can be attributed to a number of factors, such as increasing tobacco consumption in selected markets, changes in lifestyle, recurrent genetic abnormalities, and infectious diseases such as Hepatitis B and C. In various countries across the globe, people are adopting a more sedentary lifestyle, which is characterized by a high-calorie diet (that is rich in fat, refined carbohydrates, and animal protein) and low physical activity.

Restraint: Availability of high-throughput techniques

Traditional studies used FISH to analyze chromosomal abnormalities such as rearrangements, large deletions, and duplications. However, this method is limited by its low resolution or narrow target range. Due to recent advancements in high-throughput technologies, researchers are using genetic tools to overcome these limitations as these tools offer wide genome coverage with a higher resolution.

Opportunity: Companion diagnostics for cancer treatment

Companion diagnostic products demonstrate significant potential to improve the diagnosis and treatment of cancer. FISH-based biomarkers play a significant role in the development of companion diagnostics because of their ability to simultaneously evaluate morphology and gene amplification. The market for companion diagnostics is steadily growing, as personalized medicine improves patient care and assists in managing healthcare costs. Moreover, companion diagnostics enables patients to receive targeted treatments, particularly in the treatment of cancer.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829

Critical questions the report answers:

# Where will all these developments take the In situ Hybridization market in the long term?
# What are the upcoming trends for the In situ Hybridization market?
# Which segment in the In situ Hybridization market provides the most opportunity for growth?
# Who are the leading vendors operating in this In situ Hybridization market?
# What are the opportunities for new market entrants in the In situ Hybridization market?

Factors such as growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the in situ hybridization market in this region. Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are some of the pivotal factors driving the growth of the global in situ hybridization market.

The key strategies adopted by the major players include new product development, mergers & acquisitions, expansion, partnerships, agreements, and collaborations with other players in the in-situ hybridization landscape to meet the demand of their end users.

Major players operating in the global in-situ hybridization market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and Agilent Technologies, Inc. (U.S.).

Abbott (U.S.) contributed the largest share to the global in-situ hybridization market in 2014. The company has been focusing on acquisitions to maintain its leading position in the market. For instance, In December 2014, Abbott acquired Veropharm, which is a Russian manufacturer of pharmaceuticals. The acquisition not only helped the company to establish itself in the manufacturing sector but also expanded its medicine portfolio.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=212028829

F. Hoffmann-La Roche Ltd. (Switzerland) is another major player operational in the global in-situ hybridization market. F. Hoffmann-La Roche Ltd. has been focusing on acquisition and collaborations. For instance, in February 2015, Roche acquired Signature Diagnostics AG (Signature), a Germany-based oncology and genomics company. The acquisition was aimed at integrating the acquired company with the sequencing unit of Roche, so as to enable it to develop the diagnostics for cancer patients by using expertise of Signature Diagnostics in the bio banks and NGS assays.

The mergers & acquisitions and new product development by both the key players, Abbott (U.S.) and F. Hoffmann-La Roche Ltd. (Switzerland) will help boost the growth of the global in-situ hybridization market during forecast period.

This report provides a detailed analysis of the in-situ hybridization market and segments the same on the basis of type, application, end-user and geography. Based on type, the market has been segmented into DNA in-situ hybridization and RNA in-situ hybridization. Based on application, the market has been segmented into cancer diagnostics, immunology, neurosciences, cytology, and others. Based on end user, the market has been segmented into hospitals, pharma & biotech companies, research labs, and contract research organizations (CROs). Based on geography, the market has been segmented into regions, such as the North America, Europe, and Asia-Pacific.

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Sanjay Gupta
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]